Great Lakes Advisors LLC Lowers Position in Zoetis Inc. (NYSE:ZTS)

Great Lakes Advisors LLC reduced its stake in Zoetis Inc. (NYSE:ZTSGet Rating) by 6.4% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 40,848 shares of the company’s stock after selling 2,778 shares during the quarter. Great Lakes Advisors LLC’s holdings in Zoetis were worth $7,703,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Jacobi Capital Management LLC raised its position in Zoetis by 11.8% in the 1st quarter. Jacobi Capital Management LLC now owns 4,426 shares of the company’s stock valued at $835,000 after buying an additional 466 shares during the last quarter. Los Angeles Capital Management LLC raised its position in Zoetis by 5.0% in the 1st quarter. Los Angeles Capital Management LLC now owns 161,179 shares of the company’s stock valued at $30,397,000 after buying an additional 7,719 shares during the last quarter. Motco raised its position in Zoetis by 1.1% in the 1st quarter. Motco now owns 44,317 shares of the company’s stock valued at $8,358,000 after buying an additional 475 shares during the last quarter. Camden Capital LLC raised its position in Zoetis by 46.5% in the 1st quarter. Camden Capital LLC now owns 1,601 shares of the company’s stock valued at $302,000 after buying an additional 508 shares during the last quarter. Finally, Balentine LLC grew its stake in Zoetis by 47.6% in the 1st quarter. Balentine LLC now owns 3,679 shares of the company’s stock valued at $694,000 after purchasing an additional 1,186 shares during the period. 90.73% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Zoetis news, Director Willie M. Reed sold 1,855 shares of the firm’s stock in a transaction dated Friday, June 10th. The stock was sold at an average price of $162.31, for a total value of $301,085.05. Following the completion of the transaction, the director now owns 6,782 shares in the company, valued at approximately $1,100,786.42. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Zoetis news, Director Willie M. Reed sold 1,855 shares of the firm’s stock in a transaction dated Friday, June 10th. The stock was sold at an average price of $162.31, for a total value of $301,085.05. Following the completion of the transaction, the director now owns 6,782 shares in the company, valued at approximately $1,100,786.42. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Roxanne Lagano sold 4,334 shares of the firm’s stock in a transaction dated Monday, June 27th. The stock was sold at an average price of $175.00, for a total value of $758,450.00. Following the completion of the transaction, the executive vice president now owns 23,687 shares of the company’s stock, valued at approximately $4,145,225. The disclosure for this sale can be found here. Insiders sold a total of 18,356 shares of company stock worth $3,250,158 in the last quarter. 0.12% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on ZTS. Piper Sandler began coverage on Zoetis in a research note on Monday, July 11th. They issued an “overweight” rating and a $205.00 price objective for the company. StockNews.com downgraded Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, April 26th. Stifel Nicolaus reduced their price objective on Zoetis from $275.00 to $225.00 and set a “buy” rating for the company in a research note on Friday, June 24th. Finally, The Goldman Sachs Group reduced their price objective on Zoetis from $208.00 to $202.00 and set a “buy” rating for the company in a research note on Thursday, July 21st. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, Zoetis has a consensus rating of “Moderate Buy” and a consensus price target of $224.88.

Zoetis Stock Up 0.2 %

ZTS stock opened at $174.61 on Friday. The company has a debt-to-equity ratio of 1.12, a quick ratio of 1.58 and a current ratio of 2.25. The company has a market capitalization of $82.18 billion, a price-to-earnings ratio of 40.05, a PEG ratio of 3.06 and a beta of 0.73. Zoetis Inc. has a fifty-two week low of $154.18 and a fifty-two week high of $249.27. The stock has a fifty day moving average of $171.80 and a 200-day moving average of $181.35.

Zoetis (NYSE:ZTSGet Rating) last posted its quarterly earnings results on Thursday, August 4th. The company reported $1.20 earnings per share for the quarter, missing the consensus estimate of $1.22 by ($0.02). The firm had revenue of $2.10 billion for the quarter, compared to the consensus estimate of $2.03 billion. Zoetis had a return on equity of 49.62% and a net margin of 26.27%. The firm’s revenue was up 7.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.19 EPS. As a group, equities research analysts predict that Zoetis Inc. will post 5.04 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 1st. Shareholders of record on Thursday, July 21st will be paid a $0.325 dividend. The ex-dividend date is Wednesday, July 20th. This represents a $1.30 annualized dividend and a yield of 0.74%. Zoetis’s dividend payout ratio is currently 29.82%.

Zoetis Company Profile

(Get Rating)

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Featured Stories

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTSGet Rating).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.